- |||||||||| fostroxacitabine bralpamide (MIV-818) / Medivir
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations (clinicaltrials.gov) - Sep 11, 2023 P1/2, N=53, Active, not recruiting, Clinical trial information: NCT03781934. Recruiting --> Active, not recruiting | N=102 --> 53 | Trial completion date: May 2023 --> Feb 2024 | Trial primary completion date: May 2023 --> Feb 2024
- |||||||||| fostroxacitabine bralpamide (MIV-818) / Medivir
A triple combination of fostrox (MIV-818) with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo (Section 14; Poster Board #27) - Mar 14, 2023 - Abstract #AACR2023AACR_4913; P1/2 The triple combination of fostrox with anti-PD1 and lenvatinib showed enhanced efficacy in a nonclinical tumor model, and changes in TILs were consistent with increased immune-mediated anti-tumor activity. The results indicate a potential for increased anti-tumor efficacy using a triple combination of fostrox plus checkpoint inhibition and anti-angiogenic therapy.1The study was approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio UK, and conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)
- |||||||||| fostroxacitabine bralpamide (MIV-818) / Medivir
Fostrox (MIV-818) in combination with anti-PD-1 shows increased efficacy in nonclinical tumor models in vivo (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_790; P1/2 The results indicate a potential for combining anti-PD1 with fostrox in the treatment of HCC. Ethics Approval The study was approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio UK, and conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)
- |||||||||| fostroxacitabine bralpamide (MIV-818) / Medivir
Enrollment open: A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations (clinicaltrials.gov) - Feb 11, 2022 P1/2, N=102, Recruiting, Ethics Approval The study was approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio UK, and conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) Active, not recruiting --> Recruiting
- |||||||||| fostroxacitabine bralpamide (MIV-818) / Medivir
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations (clinicaltrials.gov) - Oct 14, 2021 P1/2, N=102, Active, not recruiting, No impact of MIV-818 observed in healthy liver tissue, supporting the proof-of-concept for MIV-818 liver tumour targeting. Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> May 2023 | Trial primary completion date: Dec 2021 --> May 2023
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), MIV-818 / Medivir
MIV-818 stimulates an antitumor immune response in vitro and enhances the effects of pembrolizumab (Board 56: Level 2 - Hall D) - Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_488; These effects are further enhanced in combination with pembrolizumab and support future combination of MIV-818 with PD-(L)1 inhibitors in patients with HCC and other liver cancers. The effects of MIV-818 on tumor immune activation markers are being assessed the ongoing phase 1/2 clinical trial.
|